Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation.

Shen, Gang; Shi, Lei; Tian, Xin; Huang, Depei; Chen, Hao; Gao, Chan; Shen, Xudong; Zhang, Hushan.

Afiliação

Shen G; Department of Thoracic Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Shi L; Department of Thoracic Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Tian X; Department of Head and Neck Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Huang D; The Medical Department, 3D Medicines Inc., Shanghai, China.
Chen H; The Bioinformatics Department, 3D Medicines Inc., Shanghai, China.
Gao C; The Medical Department, 3D Medicines Inc., Shanghai, China.
Shen X; The Medical Department, 3D Medicines Inc., Shanghai, China.
Zhang H; The Medical Department, 3D Medicines Inc., Shanghai, China.

Front Pharmacol ; 12: 731895, 2021.

Article em En | MEDLINE | ID: mdl-34987382